Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYMPHONY: Tigozertinib in EGFR-mutant NSCLC
NCT04862780Phase 1Terminated
- Sponsor
- Blueprint Medicines
- Start
- Jun 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 1, open-label trial of tigozertinib in non-small cell lung cancer (NSCLC) (6 arms), sponsored by Blueprint Medicines. Primary endpoints: Maximum Tolerated Dose at 12 months, Recommended Phase 2 Dose at 12 months and 2 more. Started Jun 2021; status: terminated.
02
Drugs
tigozertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04862780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04862780.